Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: Results from an international randomized controlled trial

被引：4
|
作者：
Peeters, P
Kazek, M
Abella, I
Noble, I
机构：
[1] Quintiles SA, Lewin Grp, F-92594 Levallois Perret, France
[2] Novartis Pharma AG, Basel, Switzerland
来源：
TRANSPLANTATION PROCEEDINGS | 1998年 / 30卷 / 05期
关键词：
D O I：
10.1016/S0041-1345(98)00450-3
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1838 / 1842
页数：5
相关论文
共 50 条
  • [1] Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients
    Trull, A
    Steel, L
    Sharples, L
    Stewart, S
    Parameshwar, J
    McNeil, K
    Wallwork, J
    THERAPEUTIC DRUG MONITORING, 1999, 21 (01) : 17 - 26
  • [2] Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral
    Marsh, CL
    THERAPEUTIC DRUG MONITORING, 1999, 21 (01) : 27 - 34
  • [3] Maintenance Cognitive Stimulation Therapy: An Economic Evaluation Within a Randomized Controlled Trial
    D'Amico, Francesco
    Rehill, Amritpal
    Knapp, Martin
    Aguirre, Elisa
    Donovan, Helen
    Hoare, Zoe
    Hoe, Juanita
    Russell, Ian
    Spector, Aimee
    Streater, Amy
    Whitaker, Christopher
    Woods, Robert T.
    Orrell, Martin
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2015, 16 (01) : 63 - 70
  • [4] A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients
    Shenoy, Surendra
    Hardinger, Karen L.
    Crippin, Jeffrey
    Korenblat, Kevin
    Lisker-Melman, Mauricio
    Lowell, Jeffrey A.
    Chapman, William
    LIVER TRANSPLANTATION, 2008, 14 (02) : 173 - 180
  • [5] Denosumab Prevents Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: Results from a Randomized Controlled Trial
    Bonani, M.
    Frey, D.
    Brockmann, J.
    Fehr, T.
    Muller, T.
    Graf, N.
    Wuthrich, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 323 - 323
  • [6] Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
    De Simone, P.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fung, J.
    Fischer, L.
    Duvoux, C.
    Chavin, K. D.
    Koneru, B.
    Huang, M. A.
    Chapman, W. C.
    Foltys, D.
    Witte, S.
    Jiang, H.
    Hexham, J. M.
    Junge, G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (11) : 3008 - 3020
  • [7] 6-month results from randomized, international trial of cyclosporine versus tacrolimus in de novo renal transplant patients:: Progression of pre-existing diabetes and glucose abnormalities
    Marchetti, Piero
    Vincenti, Flavio
    Jenssen, Trond
    Friman, Styrbjoern
    TRANSPLANT INTERNATIONAL, 2007, 20 : 114 - 115
  • [8] Everolimus Based Immunosuppression in Hepatitis C Virus Positive De Novo Liver Transplant Recipients: 24 Month Results from a Randomized Controlled Trial.
    Saliba, F.
    Brown, R. S., Jr.
    Metselaar, H.
    Beckebaum, S.
    Duvoux, C.
    Navasa, M.
    Dong, G.
    Lopez, P.
    Nevens, F.
    LIVER TRANSPLANTATION, 2013, 19 : S100 - S101
  • [9] A randomized, controlled trial to assess the safety of switching stable renal transplant patients from sandimmun to sandimmun neoral
    Loo, CS
    Morad, Z
    Lim, TO
    Fan, KS
    Suleiman, AB
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (03) : 1328 - 1329
  • [10] EVEROLIMUS-BASED IMMUNOSUPPRESSION IN HCV POSITIVE DE NOVO LIVER TRANSPLANT RECIPIENTS: 24-MONTH RESULTS OF A RANDOMIZED CONTROLLED TRIAL
    Saliba, F.
    Metselaar, H. J.
    Beckebaum, S.
    Duvoux, C.
    Navasa, M.
    Dong, G.
    Lopez, P.
    Nevens, F.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S79 - S80
12345